Skip to main content

Table 2 Patient characteristics in the two groups that received different neoadjuvant chemotherapy with Cisplatin and Doxorubicin and patients from Algeria who received Cisplatin and 5 FU

From: Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency

  

Algeria

Other countries

 
  

n = 119

n = 155

 

Measurement

 

n (%)

n (%)

P-value

Age (years)*

 

42.8 ± 13.3

41.0 ± 15.0

0.303

Gender

Male

82 (68.9)

116 (74.8)

 
 

Female

37 (31.1)

39 (25.2)

0.277

WHO histology

1-2

24 (20.2)

42 (27.1)

 
 

3

95 (79.8)

113 (72.9)

0.184

Stage

T3-4&N2-3

27 (22.7)

43 (27.7)

 
 

Others

92 (77.3)

112 (72.3)

0.342

  1. *Value is mean ± standard deriation.
  2. P-values ≤ 0.05 are considered significant.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us